Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336630 | 1.00 | GPR119 (0.46) | GPR119DPP4MMP13STSKMT2A | |
| SCHEMBL23826712 | 1.00 | GPR119 (0.46) | GPR119DPP4MMP13STSKMT2A | |
| SCHEMBL23826048 | 0.88 | DPP4 (0.46) | GPR119DPP4MMP13STSKMT2A | |
| SCHEMBL23826051 | 0.88 | DPP4 (0.46) | GPR119DPP4MMP13STSKMT2A | |
| SCHEMBL31336499 | 0.87 | DPP4 (0.48) | GPR119DPP4MMP13STSKMT2A | |
| SCHEMBL23827019 | 0.87 | DPP4 (0.48) | GPR119DPP4MMP13STSKMT2A | |
| SCHEMBL23826456 | 0.87 | DPP4 (0.48) | GPR119DPP4MMP13STSKMT2A | |
| SCHEMBL23826863 | 0.87 | STS (0.40) | GPR119DPP4STSKMT2AMEN1 | |
| SCHEMBL23826314 | 0.87 | STS (0.40) | GPR119DPP4STSKMT2AMEN1 | |
| SCHEMBL23826013 | 0.87 | GPR119 (0.45) | GPR119DPP4MMP13STSKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | NIPPON SHINYAKU CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| EP-3882239-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2021-09-22 | — | — | EP | disclosed |
| CN-113302184-A | 1,3, 4-oxadiazolinone compounds and drugs | 日本新药株式会社 | 2021-08-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024921-A1 | 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL | PIM1, PIM3, PIM2 | GPR119 3488/4885DPP4 32/4885MMP13 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.